About Deep Bio
Deep Bio is a South Korea-based artificial intelligence healthcare company pioneering AI-powered solutions for cancer pathology diagnostics. The company develops the DeepDx® suite of diagnostic support software that analyzes whole slide images (WSIs) of tissue specimens to detect and classify cancer with high accuracy. Their flagship products focus on prostate and breast cancer pathology, utilizing deep learning algorithms to analyze H&E-stained slides and provide automated Gleason scoring, tumor quantification, and grade group classification. Deep Bio's technology empowers pathologists by providing metrics that are difficult to measure manually, optimizing diagnostic accuracy and treatment decisions. The company's solutions support multiple clinical workflows including first read, concurrent read, quality control, research and development, and education. Their algorithms have been extensively validated through peer-reviewed publications in prestigious medical journals and have achieved regulatory approvals including CE marking and Korea MFDS approval. The company is expanding its product portfolio to include IHC analysis for biomarkers such as Ki-67, ER, PR, HER2, PD-L1, and c-MET across multiple cancer types. Deep Bio also offers DeepCDx™, an AI-enabled drug discovery platform that combines pathology image analysis with clinical data to accelerate pharmaceutical development. With over 700,000 cores analyzed, 38 patents, 25+ publications, and partnerships with leading organizations like Roche and PathAI, Deep Bio is advancing the integration of AI into clinical pathology practice globally.
Mission & Story
Mission
Deep Bio strives to achieve the highest level of accuracy, sensitivity and specificity by our AI software to become a reliable partner for our users and create values for the healthcare industry.
Clinical Focus
Medical conditions and clinical areas addressed by Deep Bio.
Who It Serves
Milestones & Awards
Recent Milestones
Collaboration with Roche announced September 2024, collaboration with PathAI announced November 2024, MOU with ABION for AI-driven companion diagnostics September 2024, multiple research presentations at AACR 2025, USCAP 2025, AUA 2024, ECP 2024
Awards & Recognition
Edison Award 2021 Silver in Cellular Research & Disease Prevention category for DeepDx Prostate, First place winner in Camelyon17 Grand Challenge for breast cancer lymph node metastasis detection
Key Partnerships
Social & Media
Follow on
Latest Updates
[Posters] AACR 2025 – Artificial intelligence-based quantification of PD-L1 staining intensity in non-small cell lung cancer: Beyond binary assessment
[Posters] USCAP 2025 – A Study on Improving the Performance of Breast Lesion Classification Using Nuclei Information
[Posters] USCAP 2025 – A Deep Learning-Based IHC Tumor Cellular Membranous Staining Analysis for PD-L1 Assessment in Non-Small Lung Cancer
Deep Bio’s AI Algorithm Demonstrates Significant Prognostic Advancements in Prostate Cancer Study
[Posters] AACR 2025 – Deep Learning Model for Cancer Diagnosis in Frozen Section Sentinel Lymph Nodes with Limited
Company Details
- Headquarters
- Seoul, Guro-gu, South Korea
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.